Evidence map›Paper›PMID 42360416›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Synthesis and biological evaluation of benzyloxymethyl-substituted imidazo[1,2-a]pyridines as apoptosis-inducing anticancer agents through modulation of BCL-2/Bax signaling and caspase-3 activation.

Ege Arzuk, İbrahim Pinar, Burak Kuzu

Abstract read
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ege ArzukDepartment of Pharmaceutical Toxicology, Faculty of Pharmacy, Ege University, İzmir, 35040, Türkiye.
İbrahim PinarDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Van Yuzuncu Yil University, Van, 65080, Türkiye.
Burak KuzuDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Van Yuzuncu Yil University, Van, 65080, Türkiye. burakkuzu@yyu.edu.tr.ORCID 0000-0002-7305-7177

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel series of benzyloxymethyl-substituted imidazo[1,2-a]pyridine derivatives (IPO1-IPO14) was designed, synthesized, and evaluated as potential anticancer agents. The compounds were synthesized via an efficient multistep strategy with satisfactory yields and structurally characterized by comprehensive

Indexed as

Antineoplastic AgentsApoptosisbcl-2-Associated X ProteinCaspase 3Proto-Oncogene Proteins c-bcl-2PyridinesCell Line, TumorCell ProliferationHumansMDA-MB-231 CellsMembrane Potential, MitochondrialMolecular Docking SimulationSignal TransductionStructure-Activity RelationshipAntineoplastic AgentsBAX protein, humanbcl-2-Associated X ProteinBCL2 protein, humanCASP3 protein, humanCaspase 3Proto-Oncogene Proteins c-bcl-2PyridinesAnticancer agentsApoptosisBaxBCL-2Caspase-3Imidazopyridine

Identifiers

PMID42360416
PMCPMC13593677

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.